


Newsletter No. 2. November 2011

headandneck 5000



Currently 6 sites are open and 162 participants have been recruited. 4 sites have local R&D approval and will soon be open to recruitment. 12 sites are currently awaiting local R&D approval. 7 sites are preparing for local R&D submission.

11 new sites have expressed interest!



H&N5000 SITES

Open

BRI Bristol
RUH Bath
Aintree
The Christie
Coventry
Leighton Hospital

Awaiting Final checks

Portsmouth
Royal Glamorgan
University Hospital, Wales
Royal Marsden

Awaiting R&D Approval

Bradford
Imperial College Charing Cross
Leeds
Manchester Royal Infirmary
North Lincolnshire and Goole
Northwick Park Hospital
Pennine (North Manchester)
Poole
Royal Surrey
UCLH London
Walsall
York

Preparing Submission


Mount Vernon
Newcastle
Northampton
South Tees
Southend
St Georges
Wolverhampton

Interested

Addenbrookes
Royal Sussex, Brighton
Colchester Hospital University
Norfolk & Norwich
John Radcliffe, Oxford
Kent & Medway
Lancashire & South Cumbria
Broomfield, Chelmsford
Luton & Dunstable
Grimsby
East Sussex, Eastbourne

The New Tissue Collection SOP has now been circulated to all open sites.

The Data Capture Forms have been amended and will be circulated in November.



The above graph shows the current questionnaire return rate; please encourage patients to return the questionnaires.

As you know it is time consuming to have to go back and verify each detail to resolve a query, so accuracy when completing the initial Data Capture forms is extremely valuable.

Frequently Asked Questions V.3

Are thyroid cancer cases eligible?

Yes. All new cases of head and neck cancer that go through the head & neck MDT are eligible

Is a patient with secondary tumour in the head and neck eligible?

No, the primary must be in the head and neck.

Are patients with a lymphoma eligible to take part?

No, patients with lymphomas are not eligible for H&N5000

Do patients need to have histological evidence or is a clinical diagnosis enough?

To be eligible for the study a clinical diagnosis of head and neck cancer is sufficient.

How do I allocate patient study ID numbers?

The first two digits are the site number and last four allocated sequentially by site. E.g. if your site is 11 your first patient will be 0001, making the full patient number 110001

How long after consent do I have to take blood & saliva samples and complete questionnaires?

The baseline samples and questionnaires must be completed before the patients initial treatment begins

How do I find the patients HPV status?

This will be mentioned in the patients pathology report.

Does the staging include radiological staging?

Yes – we need the final staging before treatment commences

What do I tick if the tumour is bilateral?

In this instance please tick both the left and the right boxes

Does 'malignancy' in the comorbidities section include the current tumour?

No – please do not include the current head and neck cancer when evaluating the patients comorbidities.

Are patients with Carcinoma in situ eligible for the study?

Not unless 'invasion' is present

Are patients with a basal cell skin cancer or melanoma of the skin in the head and neck eligible?

No, patients with skin cancers are not eligible for this study

THANK YOU FOR ALL YOUR WORK SO FAR!

H&N5000 website: www.headandneck5000.org.uk